Gaudium IVF and Women Health Q2 Results 2026: PAT ₹9 Cr +0%
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹37Cr
- +17.9% YoY
- +93% QoQ
- Net profit
- ₹9Cr
- +0.3% YoY
- +428.7% QoQ
- Margin
- 36.01%
- −7.4 pp YoY
- +23.5 pp QoQ
Guidance rank: #20 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Gaudium IVF and Women Health Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for quarter ended September 30, 2026: ₹3,741.11 lakhs (Consolidated), ₹2,805.68 lakhs (Standalone).
As stated in Gaudium IVF and Women Health Ltd's Q2 FY27 results statement · published 13 Nov 2026. Reported figures, not investment advice.
Based on Gaudium IVF and Women Health Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for quarter ended September 30, 2026: ₹3,741.11 lakhs (Consolidated), ₹2,805.68 lakhs (Standalone).
From Gaudium IVF and Women Health Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.
How did Gaudium IVF and Women Health's revenue grow in the September 2026 quarter?
- Revenue from operations for quarter ended September 30, 2026: ₹3,741.11 lakhs (Consolidated), ₹2,805.68 lakhs (Standalone)
- Revenue from operations for quarter ended September 30, 2025: ₹3,173.04 lakhs (Consolidated), ₹2,294.58 lakhs (Standalone)
- Year-on-year growth (Consolidated): ₹3,741.11 lakhs vs ₹3,173.04 lakhs, approx. 18% increase
- Year-on-year growth (Standalone): ₹2,805.68 lakhs vs ₹2,294.58 lakhs, approx. 22% increase
What happened to Gaudium IVF and Women Health's margins in Q2 FY27?
Profit before tax is ₹1,262.39 lakhs compared to ₹244.98 lakhs in the quarter ended Sep 30, 2025,…
Locked: what Gaudium IVF and Women Health Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Gaudium IVF and Women Health planning?
- Capital expenditure of ₹5,000 Lakhs allocated for establishing 19 new IVF centres.
- No change in total capex amount for this object.
- Substitution of 6 city locations proposed for IVF centres.
- Revised timeline: All 19 centres to be established by Fiscal 2029.
- Indicative targets: 10 centres in FY27, 8 centres in FY28, and 1 centre in FY29.
2 more points from Gaudium IVF and Women Health Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Gaudium IVF and Women Health raising money or cutting debt?
The company completed its Initial Public Offering (IPO) during the financial year ended March 31, 2026,…
Locked: what Gaudium IVF and Women Health Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Gaudium IVF and Women Health's order book?
See what Gaudium IVF and Women Health Ltd said on order book & pipeline — free account, 30 seconds.
Gaudium IVF and Women Health Ltd — Quarterly revenue & net profit
Gaudium IVF and Women Health Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 37 |
| Operating profit (EBITDA) | 13 |
| Operating margin | 36% |
| Profit before tax | 13 |
| Net profit (PAT) | 9 |
| EPS (₹) | 1.29 |
Source: Gaudium IVF and Women Health Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹37 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Healthcare Services
Continue your research
What Gaudium IVF's management said in earlier quarters
Others in Healthcare Services this season
- Manipal Health (Q2 FY27)
Revenue from operations for Q2 FY27: INR 3,399 crore, up 37.3% year-on-year (vs INR 2,475 crore in Q2 FY26). Key investor presentation takeaways from Manipal He
- Park Medi World (Q2 FY27)
other income) was ₹5,110 mn, a 25% YoY increase from ₹4,102 mn in Q2 FY’26. Key investor presentation takeaways from Park Medi World Ltd's Q2 FY27 investor pres
- Nephro Care (Q2 FY27)
Income from IPD Services: ₹1,915.45 Lakhs . Key results statement takeaways from Nephro Care India Ltd's Q2 FY27 results statement — and how it ranks against se
- Lotus Eye Hospit (Q2 FY27)
1,303.84 lakhs for the quarter ended September 30, 2025, indicating a year-on-year increase of approximately 36%. Key results statement takeaways from Lotus Eye
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gaudium IVF and Women Health Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gaudium IVF and Women Health Ltd Q2 FY27 results?
Revenue from operations for quarter ended September 30, 2026: ₹3,741.11 lakhs (Consolidated), ₹2,805.68 lakhs (Standalone).
What is Gaudium IVF and Women Health Ltd share price analysis?
Gaudium IVF and Women Health Ltd currently shows a neutral. The stock trades at a P/E of 33.7 with a market cap of ₹780 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gaudium IVF and Women Health Ltd planning capital expenditure?
Capital expenditure of ₹5,000 Lakhs allocated for establishing 19 new IVF centres.
Keep Gaudium IVF and Women Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.